secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001193125-23-072646
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Eliem Therapeutics Announces CFO Resignation and Appoints New Principal Financial and Accounting Officers
--------------------------------------------------------------------------------

- Erin Lavelle resigned as EVP, COO, and CFO effective March 10, 2023.
- Andrew Levin, Executive Chairman, appointed as principal financial officer (in addition to principal executive officer).
- Emily Pimblett, Chief Accounting Officer, appointed as principal accounting officer.
- Levin is a co-founder and managing director at RA Capital Management; Pimblett previously held roles at DomainTools and Avvo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312523072646/0001193125-23-072646-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312523072646/d461584d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-072646

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer